These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6932992)

  • 1. Chemotherapy and immunotherapy for acute myelogenous leukemia.
    Lister TA; Whitehouse JM; Oliver RT; Bell R; Johnson SA; Wrigley PF; Ford JM; Cullen MH; Gregory W; Paxton AM; Malpas JS
    Cancer; 1980 Nov; 46(10):2142-8. PubMed ID: 6932992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for acute myelogenous leukemia.
    Powles RL; Lister TA; Crowther D; McElwain T; Alexander P; Fairley GH
    Bibl Haematol; 1975; (40):737-49. PubMed ID: 1057948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy of adult acute leukemia.
    McCredie KB; Bodey GP; Freireich EJ; Hester JP; Rodriguez V; Keating MJ
    Cancer; 1981 Mar; 47(6):1256-61. PubMed ID: 6939477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remission maintenance for acute nonlymphocytic leukemia: cytosine arabinoside plus 6-thioguanine versus a sequence of drug regimens.
    Presant CA; Berger NA; Klahr C; Phillips GL
    Cancer; 1980 Jul; 46(1):22-8. PubMed ID: 6930320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC.
    Hayat M; Jehn U; Willemze R; Haanen C; Zittoun R; Monconduit M; Lowenberg B; Stryckmans P; Peetermans M; De Cataldo F
    Cancer; 1986 Aug; 58(3):617-23. PubMed ID: 3524789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active immunotherapy for the treatment of acute myelogenous leukaemia: report of two controlled trials.
    Whittaker JA; Bailey-Wood R; Hutchins S
    Br J Haematol; 1980 Jul; 45(3):389-400. PubMed ID: 7000149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for acute myelogenous leukaemia.
    Powles RL; Crowther D; Bateman CJ; Beard ME; McElwain TJ; Russell J; Lister TA; Whitehouse JM; Wrigley PF; Pike M; Alexander P; Fairley GH
    Br J Cancer; 1973 Nov; 28(5):365-76. PubMed ID: 4271320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient.
    Powles RL; Russell J; Lister TA; Oliver T; Whitehouse JM; Malpas J; Chapuis B; Crowther D; Alexander P
    Br J Cancer; 1977 Mar; 35(3):265-72. PubMed ID: 322689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoimmunotherapy for maintenance in acute myeloblastic leukemia.
    Whiteside MG; Cauchi MN; Paton C; Stone J
    Cancer; 1976 Oct; 38(4):1581-6. PubMed ID: 1068741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.
    Harris R; Zuhrie SR; Freeman CB; Taylor GM; MacIver JE; Geary CG; Delamore IW; Hull PJ; Tooth JA
    Br J Cancer; 1978 Feb; 37(2):282-8. PubMed ID: 272913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
    Zuhrie SR; Harris R; Freeman CB; MacIver JE; Geary CG; Delamore IW; Tooth JA
    Br J Cancer; 1980 Mar; 41(3):372-7. PubMed ID: 6992827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of acute myeloid leukaemia. Medical Research Council.
    Br J Cancer; 1978 Jan; 37(1):1-14. PubMed ID: 339940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy.
    Omura GA; Vogler WR; Lefante J; Silberman H; Knospe W; Gordon D; Jarrell R
    Cancer; 1982 Apr; 49(8):1530-6. PubMed ID: 7039813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of immunotherapy in acute myelogenous leukemia.
    Foon KA; Smalley RV; Riggs CW; Gale RP
    Arch Intern Med; 1983 Sep; 143(9):1726-31. PubMed ID: 6577818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of adult acute myelogenous leukaemia.
    Crowther D; Powles RL; Bateman CJ; Beard ME; Gauci CL; Wrigley PF; Malpas JS; Fairley GH; Scott RB
    Br Med J; 1973 Jan; 1(5846):131-7. PubMed ID: 4513355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of immunotherapy on survival of patients with acute myelogenous leukaemia after relapse.
    Powles R; Toy JL
    Haematologia (Budap); 1976; 10(1):5-9. PubMed ID: 1070466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for remission maintenance in acute myeloblastic leukemia.
    Baker MA; Taub RN; Carter WH
    Cancer Immunol Immunother; 1982; 13(2):85-8. PubMed ID: 6760961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of 100 acute myeloid leukemias (author's transl)].
    Fière D; Martin C; Vu Van H; Coiffier B; Felman P; Bryon PA; Favre-Gilly J; Revol L
    Sem Hop; 1979 Apr 8-15; 55(13-14):633-8. PubMed ID: 224478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy.
    Granatek CH; Ezaki K; Hersh EM; Keating MJ; Rasmussen S
    Cancer; 1981 Jan; 47(2):272-9. PubMed ID: 7006793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved remission induction rate with D-ZAPO but unimproved remission duration with addition of immunotherapy to chemotherapy in previously untreated children with ANLL.
    Baehner RL; Bernstein ID; Sather H; Higgins G; McCreadie S; Chard RL; Hammond D
    Med Pediatr Oncol; 1979; 7(2):127-39. PubMed ID: 291771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.